Actinogen Medical LimitedASX: ACW

ACW HY26 results - XanaMIA pivotal Alzheimers trial progress

· Issued by Actinogen Medical Limited

Filed with ASX · · 5 pages · English

Summary by 6ix AI

Actinogen Medical Limited has released its interim financial results for the first half of the financial year, highlighting progress in the XanaMIA pivotal Alzheimer's trial and preparations for commercial readiness. The company completed participant enrollment in the XanaMIA trial and received positive interim safety and efficacy recommendations from the trial's Data Monitoring Committee. Actinogen reported a net loss for the period and outlined significant funding initiatives to support ongoing clinical trials and operations. The company remains optimistic about its prospects, with the next key results from the XanaMIA trial expected in the near future.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Actinogen Medical Limited on 6ix

Story so far

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases